Oral shrimp vaccine gets market launch funding

Quoc Viet was the first shrimp farm to apply for and receive ASC Shrimp Standard certification

A funding round worth US$8.25m will enable the commercial scale-up of an oral vaccine for shrimp

Biotech company, ViAqua Therapeutics, has completed a US$8.25 million funding round to help market its orally-administered vaccine for shrimp.

The company teamed up with S2G Ventures with participation from Rabo Ventures, The Trendlines Group, Agriline Limited, Nutreco, I-Lab Angels and Circle Investments to raise the funds.

This is premium content

Already a member? SIGN IN now


Sign up for FREE to continue reading!

Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy:

  • Weekly newsletters providing valuable news and information on the commercial fishing and aquaculture sector
  • Full access to our news archive
  • Live and archived webinars, podcasts and videos
  • Articles on innovations and current trends in the commercial fishing industry
  • Our extensive archive of data, research and intelligence

Get more free content sign up today

Ready to subscribe? Choose from one of our subscription packages for unlimited access!